Etanercept biosimilar - AvesthaGen
Alternative Names: Avent™Latest Information Update: 17 Nov 2021
At a glance
- Originator Avesthagen
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 01 Mar 2016 No recent reports on development identified - Phase-III for Rheumatoid arthritis in India (SC)
- 17 Jun 2011 Etanercept biosimilar - AvesthaGen is available for global licensing as of 17 Jun 2011. http://www.avesthagen.com/
- 17 Jun 2011 Phase-III clinical trials in Rheumatoid arthritis in India (SC)